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Background: Recent evidence suggests that the effects of certain food additives may be synergistic or additive.
Aspartame (ASP) and Monosodium Glutamate (MSG) are ubiquitous food additives with a common moiety: both
contain acidic amino acids which can act as neurotransmitters, interacting with NMDA receptors concentrated in
areas of the Central Nervous System regulating energy expenditure and conservation. MSG has been shown to
promote a neuroendocrine dysfunction when large quantities are administered to mammals during the neonatal
period. ASP is a low-calorie dipeptide sweetener found in a wide variety of diet beverages and foods. However,
recent reports suggest that ASP may promote weight gain and hyperglycemia in a zebrafish nutritional model.
Methods: We investigated the effects of ASP, MSG or a combination of both on glucose and insulin homeostasis,
weight change and adiposity, in C57BL/6 J mice chronically exposed to these food additives commencing in-utero,
compared to an additive-free diet. Pearson correlation analysis was used to investigate the associations between
body characteristics and variables in glucose and insulin homeostasis.
Results: ASP alone (50 mg/Kgbw/day) caused an increase in fasting blood glucose of 1.6-fold, together with
reduced insulin sensitivity during an Insulin Tolerance Test (ITT) P < 0.05. Conversely MSG alone decreased blood
triglyceride and total cholesterol (T-CHOL) levels. The combination of MSG (120 mg/Kgbw/day) and ASP elevated
body weight, and caused a further increase in fasting blood glucose of 2.3-fold compared to Controls (prediabetic
levels); together with evidence of insulin resistance during the ITT (P < 0.05). T-CHOL levels were reduced in both
ASP-containing diets in both genders. Further analysis showed a strong correlation between body weight at
6 weeks, and body weight and fasting blood glucose levels at 17 weeks, suggesting that early body weight may be
a predictor of glucose homeostasis in later life.
Conclusions: Aspartame exposure may promote hyperglycemia and insulin intolerance. MSG may interact with
aspartame to further impair glucose homeostasis. This is the first study to ascertain the hyperglycemic effects of
chronic exposure to a combination of these commonly consumed food additives; however these observations are
limited to a C57BL/6 J mouse model. Caution should be applied in extrapolating these findings to other species.
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Aspartame (L-aspartyl-L-phenylalanine methyl ester:
ASP) and Monosodium Glutamate (MSG) are commonly
consumed food additives which are incorporated into
well over 6000 commonly consumed foods, packaged
goods and restaurant fare, where they may be ingested
together as part of a meal. The low-calorie dipeptide arti-
ficial sweetener ASP is rapidly metabolized upon inges-
tion into its metabolic components phenylalanine,
aspartate and methanol, in the ratio of 50:40:10 w/w/w
[1]. Recently, hyperglycemia and weight gain was
observed in hypercholesterolemic ASP-fed zebrafish [2];
and chronic exposure to dietary ASP over a period of 3
to 4 months has been shown to increase muscarinic re-
ceptor (mAChR) density by up to 80% in many areas of
the brain, including the hypothalamus, hippocampus and
frontal cortex [3]. mAChRs are acetylcholine receptors
highly expressed in the hypothalamus [4], and injections
of muscarine into the 3rd cerebral ventricle causes an in-
crease in hepatic venous plasma glucose levels in rats
[5]. Previous studies have linked phenylalanine consump-
tion with elevated serum insulin and glucagon levels in
healthy subjects [6], and artificial sweetener consumption
has been associated with a paradoxical increase in body
weight in several [7-9], but not all [10] epidemiological
studies.
In rodents, neonatal injections of MSG promotes obes-
ity and growth hormone defects together with hyperinsu-
linemia and elevated corticosterone levels in adulthood
[11-14]. This hypothalamic model of obesity may also be
induced in the offspring of pregnant dams orally ingest-
ing MSG [15-17]; and studies with radiolabeled 3H-glu-
tamate have shown that glutamate given orally to
pregnant mice can subsequently be detected in the ma-
ternal and fetal brains and kidneys [18]. The mechanism
behind the neuroendocrine disturbance caused by MSG
is believed to involve the glutamate-induced degener-
ation of those areas of the immature neonatal brain
which are insufficiently protected by a mature blood–
brain barrier, including regions which regulate growth
and energy metabolism [11-16]. In 1970, the Joint FAO/
WHO Expert Committee on Food Additives set an Ac-
ceptable Daily Intake (ADI) limit for MSG of 120 mg/Kg
body weight [19]. This recommendation was later revised
[20], and the Joint Expert Committee on Food Additives
(JEFCA) ruled it was not necessary to set a numerical
ADI for MSG, which is also included in the FDA’s Gen-
erally Regarded As Safe (GRAS) list [21], together with
aspartame [22].
Glutamate is one of the most abundant excitatory
neurotransmitter in the brain, and glutamate receptors
such as the N-methyl D-aspartate (NMDA) receptor are
widely dispersed throughout the central nervous system
including the amygdala, hippocampus and hypothalamus,where they regulate many vital metabolic and autonomic
functions including energy homeostasis [23], glucose sens-
ing [24], and non-insulin mediated hepatic glucose uptake
[25]. Maintaining whole-body glucose homeostasis is of
vital importance and requires the integration of hormonal
and neuronal signals activated by glucose sensors in vari-
ous parts of the body including the liver, pancreas and
brain. The hypothalamic–pituitary–adrenal (HPA) axis is
the predominant system involved in glucose homeostasis,
augmenting hepatic glycogenolysis and gluconeogenesis,
both essential components of the counter-regulatory re-
sponse to an acute decrease in blood glucose concentra-
tion. Studies have shown that during experimental
hypoglycemia, levels of the NMDA receptor ligands glu-
tamate and aspartate rise by up to 10-fold in the central
nervous system [26], indicative of a pivotal role of the
NMDA receptors in glucose regulation. The partial hyper-
glycemia induced by neonatal treatment with high-dose
injections of MSG is believed to be due to glutamate-
mediated destruction of NMDA-receptor rich neurons in
the arcuate nucleus, which leads to a higher level of adi-
pose tissue accumulation with resultant insulin resistance
and hyperinsulinemia [27,28]. Abnormal glucose homeo-
stasis may result in hyperglycemia leading to insulin resist-
ance; and the prevalence of insulin resistance and type 2
diabetes is increasing world-wide, particularly in the youth,
where it is associated with the rise in obesity [29]. Even a
mild state of unchecked hyperglycemia may be indicative
of prediabetes, a relatively new diagnosis which is defined
as having an impaired fasting glucose (IFG) (glucose
level≥ 100 mg/dL but≤ 125 mg/dL), or impaired glucose
tolerance [30].
Recent evidence suggests that the effects of food addi-
tives may be synergistic or additive [31]. Given the wide-
spread availability of ASP and MSG in a vast range of
processed foods, beverages and restaurant fare, studies
on the effects of chronic exposure to these additives
would be a timely addition to our knowledge of how re-
cent nutritional changes may influence health outcomes.
We therefore examined the effects of chronic exposure
to a combination of the food additives ASP and MSG on
glucose homeostasis and weight change, compared to ei-
ther substance on its own, or an additive-free diet. A
random-fed insulin tolerance test was used to investigate
glucose homeostasis and insulin sensitivity. Additionally
Pearson correlation analysis was used to examine the re-
lationship between variables in insulin sensitivity, adipos-
ity, body weight and other body characteristics.
Because exposure to nutritional and environmental
challenges during critical periods of early development
can markedly affect metabolism in later life [32], and
since differentiation of the rodent neuroendocrine sys-
tem regulating energy homeostasis begins during gesta-
tion and continues for a significant period of time after
Collison et al. Nutrition & Metabolism 2012, 9:58 Page 3 of 13
http://www.nutritionandmetabolism.com/content/9/1/58birth [33], our study animals were exposed to these addi-
tives in utero via the mother’s diet and throughout the
first five months of life, in a 2-factor experimental design
similar to our previous studies [34,35]. We selected a
dosage of ASP which approximates the recognized ac-
ceptable daily intake (ADI), which is currently set at
50 mg/Kg body weight in the USA [36]. Monosodium
glutamate was administered at 120 mg/Kg BW. To our
knowledge this is the first study to examine the effects of




C57BL/6 J mice were obtained from the Jackson Labora-
tory and housed/caged in a controlled environment
(Pathogen-free conditions of 12 h light/dark cycle, 22±2 °C),
and fed a standard chow diet (F648 Laboratory Animal
Pellet Diet, Grain Silos and Flour Mills Organization,
Saudi Arabia) as previously described [34,35]. See Table 1
for composition of the Standard Chow. Female breeders
were maintained on the standard chow diet until six
weeks of age whereupon they were placed on one of four
different dietary regimens for an adjustment period of
three weeks prior to mating at 9 weeks of age as described
previously [34,35]. The four dietary intervention groups
were (1) ad lib Standard Chow with ad lib drinking water
(Control diet). (2) Ad lib Standard Chow, with ad lib
drinking water containing 0.75 g/L monosodium glutam-
ate (MSG diet: L -Glutamic acid monosodium salt hy-
drate; catalog G1626 Sigma Aldrich). (3) Ad lib Standard
Chow, with ad lib drinking water containing 0.25 g/L as-
partame (ASP diet: Asp-Phe methyl ester, catalog A5139
Sigma Aldrich). (4) Ad lib Standard Chow, with ad lib
drinking water containing 0.25 g/L ASP and 0.75 g/L
monosodium glutamate (MSG+ASP diet). After the 3-
week period of adjustment to the respective diets, 18 male




Control MSG ASP MSG+ASP
Protein (%) 22.5 22.5 22.5 22.5
Carbohydrate (%) 64.2 64.2 64.2 64.2
Fat (%) (Ether extract) 5 5 5 5
Fiber (%) 3 3 3 3
Vitamins, Minerals & Ash (%) 5.3 5.3 5.3 5.3
Energy (kcal/g) 3.36 3.36 3.36 3.36
Aspartame (%) 0 0 0.025 0.025
Monosodium Glutamate (%) 0 0.075 0 0.075
Constituents are expressed as percentage of ration except where otherwise
indicated.maintained on these diets for the duration of the study.
These experimental subjects were derived from between 7
and 10 separate litters per diet / gender group (n=18).
Offspring were weaned at 4 weeks of age and housed, 3 to
a cage in an identical manner as described above. Food
and fluid intake was monitored in all animals at 7 weeks,
and again at 15 weeks of age, by weighing the food pellets
and water bottles to the nearest 0.1 g. Mean food/fluid
consumption of animals housed 3 to a cage was calculated
by subtraction. Average body weight was assessed at 6 &
17 weeks of age. Percentage weight change between these
two time-points was calculated as follows:
% weight change ¼ ðweight at 17 weeks
 weight at 6 weeksÞ=weight at 6 weeks
 100:
Mean ASP and MSG consumption were calculated
from the amount of ASP-water and MSG-water con-
sumed, and expressed in mg per Kg body weight. At the
conclusion of the study (20 weeks of age), overnight-
fasted subjects were euthanized with a mixture of xy-
lazine and ketamine, and the blood was collected by
cardiac puncture for analysis of serum components.
Concomitantly, the visceral fat (epididymal fat pads, to-
gether with the gonadal/ovarian adipose tissue associated
with the reproductive organs and the omental-
mesenteric fat associated with the digestive organs) was
carefully excised, rinsed in PBS buffer, blotted dry and
weighed to the nearest 0.01 g. The breeding and care of
the animals were in accordance with the protocols
approved by the Animal Care and Use Committee of the
King Faisal Specialist Hospital & Research Centre.
Measurement of fasting serum glucose, insulin, and lipid
profile
Overnight fasting blood glucose was measured from the
tail vein of all of the 17-week old experimental subjects
(n = 18 per diet and gender group) using the Ascensia
Contour glucometer (Bayer HealthCare, IN, USA). Add-
itionally, Serum Triglyceride (TG), T-CHOL, and HDL-C
concentrations were also measured in overnight fasted
17-week old mice using the Reflovet Plus instrument
(Roche, F. Hoffmann-La Roche Ltd, Basel, Switzerland)
as described in our previous studies [34,35]. Fasting insu-
lin was measured using the murine Insulin ELISA kit
from Mercodia (Uppsala, Sweden) according to the man-
ufacturer’s instructions.
Random fed Insulin tolerance test (ITT)
The effect of dietary ASP and MSG on glucose parameters
was determined in the same experimental subjects using a
random-fed insulin tolerance test (ITT) obtained at
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to the commencement of the ITT all animals had full ac-
cess to food and water. An intraperitoneal injection of in-
sulin (Sigma, IL) at a dose of 0.75 U/kg body weight was
administered, and whole blood glucose levels were mea-
sured from the tail vein at 0, 15, 30, 45 and 60 min after
injection. During the 60-minute test the animals did not
have access to food or water. Assessment of insulin sensi-
tivity was made after calculating the Area Under the Curve
for glucose (AUC GLUCOSE), the rate of glucose utilization
(KITT), and the half-life of glucose levels (T½). AUCs were
calculated using trapezoidal rule. KITT, defined as the per-
centage decline in glucose per minute, was calculated from
the natural log (ln) of glucose concentrations between time
t1 and t2, formula K= 100*[(ln-ln)/(t2-t1)]. The serum T½
defined as the time in minutes required for the glucose
concentration to be halved, was calculated as: T½= (0.693/
k)*100 min [37].
Statistical analysis
All analyses were performed using SASW version 9.2 (Cary
NC, USA) and SPSS version 13 (Chicago IL, USA). Data
presented as mean±SEM for 6 and 17-week body-weight,
serum lipid profile and glucose variables separately in male
and female mice (n= 18 per diet and per gender) were
analyzed using a two way ANOVA for diet and gender.
Fasting blood glucose levels was analyzed using a multiple
linear regression model to evaluate the significance of the
main effects of the diet groups MSG, ASP and MSG+ASP
and their interaction. Means of the response variable (fast-
ing blood glucose) were plotted across the levels of the in-
dependent variables (diet groups) [38,39]. A three way
ANOVA, using the mixed model in SAS was used to test
for significant differences between diet, gender, time points
and their interaction during the Insulin Tolerance Test.
Pearson correlation analysis was performed to evaluate
possible associations between output variables in the insu-
lin tolerance test and parameters relating to body weight,
fat deposition and lipid profile. Statistical significance was
set at P < 0.05.
Results
Effect of aspartame and MSG on body characteristics and
lipid profile
Mean aspartame (ASP) and MSG intake was 55.14± 4.74
and 123.44± 13 mg/Kg body weight respectively. Food and
fluid intakes at 7 and 15 weeks of age are presented in Fig-
ure 1. At the earlier time-point, male mice in the MSG+
ASP diet consumed slightly less chow than those in the
Control and MSG groups, but not statistically significantly
less than mice in the ASP diet group (Figure 1A, P < 0.05).
Additionally, 7-week old male mice in the Control diet
group consumed significantly more fluid than either of the
other 3 diet groups (Figure 1C, P< 0.05). We found nodifferences between food and fluid intake in female
7 week-old mice (Figure 1B & D), and by 15 weeks, no sig-
nificant differences in food and fluid intake between the
four diet groups were apparent in either gender. There
were no gender-wise difference between food / fluid intake
at 15 weeks of age; however at 7 weeks males in the
MSG+ASP diet consumed less chow than females; and
males in the MSG and ASP diet groups consumed slightly
more fluid than females (P< 0.05).
At 6 and 17 weeks of age, male and female body weight
in the MSG+ASP diet group was significantly elevated
above the other groups (Table 2, P < 0.01). There was a
trend towards higher visceral fat deposition in the MSG+
ASP co-treatment group which did not reach statistical
significance in both genders; however male mice in all 4
diet groups weighed significantly more than females and
the average weight of male visceral fat deposition was
twice as high as that of the females in all 4 diet groups
(P < 0.01). Fasting serum insulin levels were all within the
normal range and there were no significant differences
between the four diet groups (Table 2). However, levels of
female fasting serum insulin in the control group were
significantly lower than males (P < 0.01).
Both the MSG and the ASP diet groups exhibited
decreased levels of total blood cholesterol (T-CHOL)
and TG compared to controls (Table 2, P < 0.05), how-
ever the MSG+ASP combination did not further reduce
the level of either substance. Further effects of the food
additives on the lipid profile is suggested by a lowering
of levels of HDL-C by both MSG-containing diets (MSG,
and MSG+ASP co-treatment) in males but not females
(Table 2, P < 0.05).
Interactive effects of MSG and ASP on glucose
homeostasis
In addition to the effect of the MSG+ASP combination
treatment on body weight and fat deposition, fasting
blood glucose levels differed significantly between the 4
diet groups. Treatment with ASP alone raised levels 1.6-
fold compared to control; whereas levels in the MSG+
ASP group increased by 2.25-fold in males and 2.3-fold
in females, suggesting a synergistic effect of MSG on
ASP-induced hyperglycemia (Figure 2, P < 0.001). In
order to confirm the nature of the interaction, we used a
multiple linear regression model which indicated that
the diet combination MSG+ASP acted synergistically in
elevating fasting blood glucose levels. The average response
across the levels of the diet groups were non parallel
lines proving the presence of synergy (co-directional
interaction). The result of the analysis indicated that in-
gestion of the combination of food additives elevates
fasting blood glucose levels more than the sum of the
individual diets (Additional file 1: Figure 1S, P < 0.01).
Interestingly, levels of fasting blood glucose were
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Figure 1 Food (A,B) and fluid (C,D) intake in mice at 7 (A,C) and 15 weeks of age (B,D), according to diet groups (n = 18). Statistically
significant differences are shown using different letters a,b. Significant gender-wise differences are denoted by * P < .05.
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dicating that the mechanism behind the ASP-induced glu-
cose elevations is common to both genders.
In order to examine the effect of the food additive
treatment in more detail, we performed a random-fed in-
sulin tolerance test (ITT) on these mice at 19 weeks of
age. The ITT demonstrated insulin resistance in both
male ASP-containing diet groups compared to control
(Figure 3A, P < 0.01). Area Under the Curve analysis of
glucose levels (AUCGLUCOSE ) showed that the ASP-
containing diets (ASP and MSG+ASP) raised insulin-
challenged blood glucose levels significantly higher than
the other two diet groups, suggesting impairment of glu-
cose homeostasis in these mice (Figure 3C, P < 0.01).
There was a similar trend in females which did not reach
statistical significance (Figure 3B & D). In both MSG-
containing diet groups (MSG and MSG+ASP), the fe-
male AUC GLUCOSE was significantly lower than males,
suggesting a higher insulin-stimulated glucose response
(P < 0.05). The glucose disappearance coefficient KITT; a
measure of insulin resistance, was significantly decreased
by MSG+ASP co-treatment in both genders (Table 3,
P < 0.01). Additionally, the half-life of blood glucose (T½)
was raised by more than double by the MSG+ASP treat-
ment in male subjects, indicative of longer periods ofinsulin-stimulated hyperglycemia following chronic treat-
ment with both food additives combined. MSG treatment
alone had no apparent effect on either AUC GLUCOSE, KITT
or the half-life of glucose during the ITT.
In the control diet group, males and females shared al-
most identical AUC GLUCOSE, KITT and T½ values, sug-
gesting that glucose homeostasis was similar in both
genders under normal conditions (Table 3). Additionally
even though the glucose half-life increased in response
to ASP treatment, and the KITT decreased, the levels of
these parameters were almost identical in both genders,
indicating a shared mechanism for the ASP-induced im-
pairment in glucose homeostasis (Table 3).
Taken together our results suggest that ASP treatment
increased fasting blood glucose levels, and the combin-
ation of ASP plus MSG caused further impairment of
glucose homeostasis in both genders, which was accom-
panied by an increased body weight apparent at both 6
and 17 weeks of age. It also suggests that MSG appears
to interact with ASP in raising blood glucose levels to
prediabetes levels (≥ 100 mg/dL) in these mice.
Correlation analysis
In order to further understand the underlying mechan-
isms behind the diet-induced weight gain and glucose
Table 2 Effect of aspartame (ASP) and MSG on body weight, fat deposition and lipid profile
CONTROL MSG ASP MSG+ASP P-value Diet, Gender
6 Week Body Weight (g)
male 18.1 ± 0.26 a 17.41 ± 0.33 a 17.97 ± 0.22 a 19.39 ± 0.19 b <.0001
female 14.34** ± 0.17 14.15** ± 0.21 14.40** ± 0.15 15.95** ± 0.19 <.0001
17 Week Body Weight (g)
male 24.92 ± 0.34 a 25.61 ± 0.32 a 25.5 ± 0.31 a 27.84 ± 0.42 b <.0001
female 19.24** ± 0.19 18.70** ± 0.19 19.66** ± 0.26 21.61** ± 0.23 <.0001
Weight Change (%)†
male 37.79 ± 1.18a 46.46 ± 2.28b 42.03 ± 1.38ab 43.7 ± 2.04ab 0.06
female 34.41 ± 1.47 33.64** ± 1.28 36.67* ± 1.7 35.56** ± 1.12 <.0001
Visceral Fat (g)
male 0.31 ± 0.02 0.34 ± 0.03 0.34 ± 0.03 0.38 ± 0.03 0.189
female 0.15** ± 0.02 0.14** ± 0.01 0.13** ± 0.01 0.18** ± 0.02 <.0001
Insulin (uIU/mL)
male 8.76 ± 1.16 8.67 ± 1.7 5.43 ± 1.02 9.67 ± 1.83 0.197
female 4.61** ± 0.74 5.23 ± 0.65 4.34 ± 1.18 6.07 ± 1.20 <0.001
TG (mg/dL)†
male 124.56 ± 6.1a 92.88 ± 4.45b 95.97 ± 5.61b 125.39 ± 2.91a <.0001
female 123.11 ± 5.05a 84.47 ± 4.56b 93.54 ± 5.59b 93.27** ± 5.03b <0.01
T-CHOL (mg/dL)
male 133.33 ± 2.26 a 123.94 ± 1.19 b 118.17 ± 1.2 c 123.56 ± 1.01 b <.0001
female 133 ± 1.81 123.56 ± 1.2 122.33** ± 0.81 124.5 ± 0.92 0.276
HDL-C (mg/dL)
male 87.48 ± 5.24 a 71.19 ± 3.21 b 83.36 ± 2.39 ab 73.33 ± 2.52 b <.01
female 57.62** ± 3.17 54.46** ± 2.19 51.16** ± 2.2 49.38** ± 1.7 <.0001
Data presented are Means ± SEM (n = 18 per diet and per gender). P-values were calculated using 2-way ANOVA. Significant differences between diets are
indicated using different letters in bold abc. *,** indicates p-value of < .05 and < .01 for the comparison of males to females within each diet.
Data presented are means ± SEM.
P-values for diet and gender are calculated using two way ANOVA.
Significant differences between diets are shown using different letters abc.
† Diet*Gender interaction was found to be significant (P < 0.05). Letters abc indicate significant differences between diets separately for each gender.






























Figure 2 Effect of aspartame (ASP) and MSG on fasting glucose levels in C57Bl/6 J mice. Statistically significant differences are shown using
different letters abc (n = 18 per diet and per gender).
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Figure 3 Random-fed insulin tolerance test. Glucose levels following insulin challenge in (A) male mice and (B) female mice at
0,15,30,45 and 60 minutes after challenge. Dissimilar means are denoted by **,*** indicating p-values of < .01 and< .001. Area Under the Curve
(AUC GLUCOSE) as a measure of insulin resistance in (C) males and (D) females. Statistically significant differences are shown using different letters abc.
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observed outcome parameters, we performed Pearson
correlation analysis between ASP and MSG consump-
tion, variables in the ITT (AUC GLUCOSE, K ITT, T ½),Table 3 AUC GLUCOSE, K ITT and T½ values during a random-fed
C57Bl/6 J mice (n = 18 per gender)
CONTROL MSG
MEAN SEM MEAN SEM
Basal Glucose (mg/dL)
male 119.36a 2.80 117.92a 4.71
female 112.39ab 4.49 108.50a 1.96
AUCGLUCOSE (mg/dL.min)
male 4829.58a 131.96 5522.29ab 152.6
female 4819.93 190.36 4717.92** 76.45
K. ITT (%/min)
male 2.92a 0.28 2.10ab 0.20
female 2.60 0.37 2.28 0.26
T½GLUCOSE (min)
male 39.69a 14.05 37.91a 3.84
female 39.02 6.38 41.54 7.66
Significant differences between diets are indicated by different letters abc. *, ** indi
respectively.
P-values for comparison of diets are calculated using one way ANOVA, dissimilar me
*,** indicate p-value of < .05, <.01 when comparing males to females within each diand the body characteristics listed in Table 2. Irrespective
of diet, in both genders we identified a strong correlation
between ASP intake and fasting blood glucose levels in
males and females (Table 4, P < 0.01). MSG intakeinsulin tolerance test administered to male and female
ASP MSG+ASP p-value
MEAN SEM MEAN SEM
143.72 5.41b 122.64a 2.90 <.0001
120.33ab** 4.94 125.08b 2.30 <.01
9 5829.79bc 197.07 6454.79c 266.98 <.0001
5288.33 217.38 5057.92** 233.79 0.156
2.32a 0.29 1.15b 0.26 0.001
2.40 0.19 1.95* 0.26 0.436
51.61ab 16.63 105.56b 23.72 0.022
32.36 2.90 92.55 36.44 0.105
cate differences between males and females within each diet P < 0.05 and 0.01
ans are denoted by different letters abc.
et group.
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but was still highly significant in males and females. Fur-
ther positive correlations between ASP intake were
found with body weight at both 6 and 17 weeks of age,
and with random-fed glucose levels. Area under the
curve for glucose (AUC GLUCOSE) during the ITT, to-
gether with the half-life of glucose, correlated positively
with ASP intake. Conversely, MSG intake was associated
with weight at 17 weeks of age, % weight change in
males; and both 6-week and 17-week body weight in
females. Interestingly ASP intake correlated negatively
with total cholesterol levels in both genders, suggesting
that higher levels of ASP intake are associated with lower
levels of blood lipids. We also found a correlation be-
tween body weight at 6 weeks, and body weight and fast-
ing blood glucose levels at 17 weeks, suggesting that
early body weight may be a good predictor of glucose
homeostasis in later life. Additionally, visceral fat accu-
mulation correlated with random blood glucose in males
and fasting glucose levels in female mice. Furthermore in
both genders, percentage weight change correlated posi-
tively with visceral fat deposition together with fasting
and random blood glucose levels, suggesting that
increased weight is associated with increased adiposity
and glucose deregulation in these mice. Moreover in
both genders, early body weight correlated negatively
with percentage weight gain, indicating that a lower
post-weaning body weight may be indicative of larger
weight gains in adulthood, and vice versa.
In males but not females, 6-week body weight nega-
tively correlated with AUC GLUCOSE and the glucose
disappearance coefficient K ITT (Table 4). In females
however, the negative correlations were weaker and
without statistical significance. Additionally, further
analysis of male mice indicated that weight change
correlated positively with visceral fat and fasting glu-
cose levels, and negatively with body weight at 6 weeks
of age. Triglyceride (TG) levels correlated with early
and adulthood body weights. A subtle difference be-
tween the genders was that visceral fat deposition cor-
related with early and adult body weight together with
percentage weight gain in females, whereas male adi-
posity only correlated with adulthood body weight
and percentage weight gain.
Correlation analysis was further extended to exam-
ine the associations between these covariates when
stratified by diet and gender. Additional file 2: Table
S1 shows a diet-stratified correlation matrix. In both
genders, the rate of glucose utilization (KITT) nega-
tively correlated with the half-life of glucose (T½) in
all four diet groups (Additional file 2: Table S1A-D,
P < 0.05). In all the diet groups, 6-week body weight
correlated significantly with 17-week body weight ex-
cept for males in the MSG+ASP group, (Additionalfile 2: Table S1A-D). There were several positive cor-
relations between visceral fat and body weight in both
the MSG and MSG+ASP diet groups (both genders:
Additional file 2: Table S1B and 1D P < 0.05). In
males, fasting blood glucose correlated with MSG in-
take in the MSG diet group (Additional file 2: Table
S1B), and with both MSG and ASP intake in MSG+
ASP diet group (Additional file 2: Table S1D). Vis-
ceral fat deposition correlated with MSG intake in
both genders in the MSG diet group (Additional file
2: Table S1C), but only in females consuming both
additives (Additional file 2: Table S1D).
In summary, our data suggests that exposure to a
combination of dietary ASP and MSG may promote
an increase in body weight, adiposity and markers of
developing insulin resistance, including fasting blood
glucose elevations and impairment in insulin sensitiv-
ity. Early body weight correlated with impairment of
glucose homeostasis, and was a predictor of weight
gain and adiposity in adulthood.
Discussion
The present study suggests that neonatal exposure to as-
partame (ASP), or a combination of MSG and ASP, to-
gether with continued exposure to these additives for the
first five months of life can markedly influence glucose
homeostasis in young adult male and female C57BL/6 J
mice. Our data confirms previous findings that ASP
treatment promotes hyperglycemia and weight gain in
hypercholesterolemic zebrafish [2]. The timing of expos-
ure to these food additives appears to be critical in deter-
mining the outcome, since it has previously been shown
that acute administration of a high dose of ASP to adult
diabetic rats had no effect on plasma glucose levels [40].
In our study, exposure commenced in utero via transfer
of amino acids through the placenta, and continued dur-
ing breast-feeding and through to adulthood via the
drinking water consumed daily. Experimentally, this de-
sign resembles the patterns of exposure to food additives
which may occur in other species, such as primates.
Several studies have shown that nutrition in neonatal
and fetal life may lead to related disorders in adulthood
such as cardiovascular disease and obesity [33]. Further-
more, studies have suggested that in rodents, chronic
treatment with ASP [3,41] or MSG [42], or prenatal ex-
posure to these additives [43,44] may cause behavioral
differences and learning impairment, suggesting the pos-
sibility of an effect on centers of learning and develop-
ment in the brain [1], which are intricately linked to
insulin and glucose homeostasis [45]. Glutamate derived
from dietary MSG could cause a rapid spiking of plasma
glutamate levels compared to similar amounts of glutam-
ate bound to other amino acids in dietary proteins [46];
and since ASP is also metabolized rapidly into its two


































−0.150 0.377** 0.391** 0.055 0.153 0.723** −0.473** −0.029 0.042 0.360** 0.472** −0.270* 0.262*
MSG Intake
(mg/kg)
0.181 0.214 0.394** 0.289* 0.156 0.297** −0.066 −0.346** 0.060 −0.195 0.377** −0.384** 0.176
6 Week Body
Weight (g)
0.510** 0.467** 0.698** −0.371** 0.076 0.442** −0.221 0.028 0.379** −0.049 −0.257* −0.231* −0.022
17 Week Body
Weight (g)
0.607** 0.414** 0.812** 0.219 0.261* 0.606** −0.286* −0.042 0.228* 0.092 −0.087 −0.413** −0.119
Weight
Change (%)
0.151 −0.090 −0.299* 0.435** 0.450** 0.282* 0.064 0.070 0.082 0.294* 0.124 −0.210 −0.078
Visceral
Fat (g)
0.078 0.222 0.340** 0.400** 0.265* 0.163 −0.012 0.236* 0.035 0.335** 0.150 −0.104 0.032
Fasting Glucose
(mg/dL)
0.809** 0.378** 0.587** 0.790** 0.378** 0.269* −0.343** −0.115 0.060 0.321** −0.195 −0.417** −0.153
T-CHOL (mg/dL) −0.423** −0.222 0.030 0.031 0.142 0.196 −0.058 0.027 0.174 −0.123 −0.056 0.136 0.074
HDL-C (mg/dL) −0.263* −0.172 −0.098 −0.216 −0.237 0.014 −0.153 0.050 0.312** 0.161 −0.189 0.315** 0.200
TG (mg/dL) −0.245* −0.330** −0.053 0.015 0.161 −0.241 −0.100 0.279* 0.075 −0.369** −0.214 −0.102 0.117
Random Glucose
(mg/dL)
0.241 −0.102 0.267* 0.459** 0.306* 0.175 0.446** 0.318* −0.126 0.084 0.036 0.194 −0.003
AUCGLUCOSE
(mg/dL.min)
0.235 −0.126 −0.071 0.005 0.073 0.150 0.080 0.275* 0.173 0.076 0.338** −0.108 −0.270*
K.ITT (%/min) −0.214 −0.202 −0.017 −0.068 −0.085 −0.184 −0.145 0.139 −0.090 0.107 0.329* −0.080 0.194
T½GLUCOSE (min) 0.135 0.266* 0.214 0.218 0.041 0.235 0.255* 0.077 −0.032 −0.101 0.038 −0.066 −0.400**
Significant correlations are indicated in bold by ** at the 0.01 level and * at the 0.05 level (2-tailed). Correlations in males (n = 72) are indicated in italics (top right), and correlations in female subjects (n = 72) are shown
in the bottom left of the table.
Significant correlations are indicated in bold by ** at the 0.01 level and * at the 0.05 level (2-tailed).





















Collison et al. Nutrition & Metabolism 2012, 9:58 Page 10 of 13
http://www.nutritionandmetabolism.com/content/9/1/58amino acids phenylalanine and aspartate, which are nor-
mally only found in the bound form in dietary protein,
concerns emerged over potential neurotoxicity arising
from the interaction between ASP and MSG [47,48].
The immediate metabolic products of ASP are phenyl-
alanine, aspartate and methanol, in the ratio of
50:40:10w/w/w [1]. Phenylalanine metabolism in the
body can follow one of two pathways: conversion into
tyrosine by the hepatic enzyme phenylalanine hydroxy-
lase (PAH); alternatively it can compete with other large
neutral amino acids for binding sites on the large neutral
amino acid transporter (NAAT), to be carried across the
blood–brain barrier [1]. Both phenylalanine and tyrosine
are intimately involved in the production of several key
neurotransmitters such as dopamine, norepinephrine
and serotonin. Furthermore, phenylalanine also plays a
role in amino acid metabolism and protein structuring in
all body tissues. It has previously been shown that a sin-
gle dose of 200 mg/Kg ASP by gavage increased rodent
plasma phenylalanine and tyrosine levels by 62% and
142% respectively [49]. Elevated levels of ASP-derived
phenylalanine could potentially accumulate in the brain
owing to its ability to compete with tyrosine for the
NAAT at the blood–brain barrier. This in turn could lead
to changes in the regional brain concentrations of these
neurotransmitters; and indeed, a dose-dependent reduc-
tion in levels of dopamine, serotonin and norepineph-
rine, together with increased levels of oxidative stress
markers has recently been demonstrated in the brains of
ASP-treated mice [50]. Thus, ASP and its metabolites
have the potential to disrupt a wide range of cellular pro-
cesses including neuroendocrine balances. Further eluci-
dation of these mechanisms is discussed in greater detail
in a comprehensive review by Humphries et al [1].
Previous research has shown that hyperphenylalanine-
mic rodents have lower brain weights [51] together with
impaired myelinogenesis [52]. Interestingly, increased
hepatic glucose production and plasma glucose levels
have been reported in rats challenged with an acute load
of phenylalanine [53]. Further evidence for a mechanism
for the effects of ASP on glucose homeostasis is provided
by a study which showed that ASP may increase muscar-
inic receptor density by up to 80% in many areas of the
brain, including the hypothalamus [3]. Moreover, micro-
dialysis studies have shown that activation of muscarinic
and ACh-receptive neurons (mAChRs) in the hypothal-
amus caused an elevation in rodent plasma glucose levels,
which could be reduced by the mAChRs antagonist atro-
pine [54], suggesting a role for hypothalamic mAChRs in
glucose homeostasis.
In our study, ASP (55.14 mg/Kg BW/day) raised fast-
ing blood glucose levels by 1.6-fold, whereas a combin-
ation of ASP and MSG (123.44 mg/Kg BW/day) further
raised fasting glucose to prediabetic levels in bothgenders. The similarity in response to ASP and MSG in
terms of glucose homeostasis is particularly striking, and
points to a shared mechanism between the genders. It is
tempting to speculate that the interaction between ASP
and MSG may converge at the level of the NMDA recep-
tor for which glutamate and aspartate are both ligands;
however the situation is likely to be far more intricate.
Glutamate is the most abundant excitatory neurotrans-
mitter and plays a pivotal role in the formation of synap-
ses, integration of convergent signals, the establishment
of N-methyl-D-aspartate (NMDA) receptor-dependent
long term potentiation, and several critical autonomic
functions including appetite regulation and thermogenesis
[55]. However, elevated levels of glutamate have been
shown to cause selective neuronal damage in the brains of
infant mice, in particular the highly vascularized areas
located outside the blood–brain barrier such as the me-
dian eminence and the hypothalamic arcuate nucleus
[56,57]. Earlier research has established that the minimum
concentration of MSG required to cause injury to murine
hypothalamic neurons is 200 mg/Kg BW [58]. At this
concentration, plasma glutamate levels spiked by 16-fold
after 15 minutes of exposure; and resulted in increased
NMDA receptor expression together with accumulation
of glutamate in the hypothalamic tanycytes [58]. However,
even nonexcitotoxically-derived glutamate may affect
neurotransmission and correlates of brain glutamatergic
function [59]; this notion is supported by the finding that
elevated levels of glutamate have been shown to modulate
the expression of glutamate transporters (GLT-1 and
GLAST) without promoting overt cellular injury [59-62].
Existing evidence using 3 H-glutamate radiolabeled
tracer studies suggest that in rodents, glutamate can
cross the placental barrier and accumulate in the imma-
ture fetal central nervous system [44]. However whereas
it is generally agreed that aspartate crosses the placenta
only to a limited degree [63], phenylalanine is actively
transported across the placenta [64]; resulting in an in-
crease in phenylalanine at the expense of the maternal
concentration [65]. In rodents, phenylalanine is also
readily converted into the neurotransmitter precursor
tyrosine by the hepatic enzyme phenylalanine hydroxy-
lase (PAH) [66]; but if the activity of this enzyme is
reduced or absent, the high levels of accumulated
phenylalanine may be converted into other metabolites
such as β-Phenylpyruvate [67,68], which are known to
interfere with normal glucose metabolism [68,69]. Cru-
cially, studies have shown that in rodents, PAH activity is
absent until a late stage of gestation, or shortly after birth
[70-72]; and experimentally induced hyperphenylalanine-
mia in rats diminishes cerebral glycolysis by inhibiting
hexokinase and pyruvate kinase [73], leading to impair-
ment of glucose metabolism in the hyperphenylalanine-
mic rodent brain [74,75]. Taken together, this evidence
Collison et al. Nutrition & Metabolism 2012, 9:58 Page 11 of 13
http://www.nutritionandmetabolism.com/content/9/1/58suggests a number of potential mechanisms which could
be responsible for the perturbation in glucose homeosta-
sis that we observed. Further studies are required to ex-
plore these possibilities in more detail.
One further observation from our study shows a re-
duction in total cholesterol (T-CHOL) levels in both
male and female C57BL/6 J mice following ASP and
MSG exposure, together with a lowering of triglyceride
levels in female mice in the 3 diet groups compared to
Control. A slight reduction in serum cholesterol has also
previously been noted in Wistar rats exposed to ASP at a
concentration of 4 g/Kg/day (approximately 80 times the
ADI for ASP) for a period of approximately 24 months
[76]. In humans, ingestion of 150 mg/Kg bw for six
weeks also lowered serum cholesterol and phospholipids
[77], although the relevance of this observation to the
present rodent study is questionable. Additionally, the
mechanism behind this hypolipidemic effect remains to
be established.
Our correlation analysis revealed a positive association
between ASP intake and body weight in both genders.
As mentioned earlier, artificial sweetener intake has been
associated with increased weigh gain in several, but not
all human epidemiological studies in the past [7-10]. Our
correlation analysis also indicated that early body weight
may be a good predictor of glucose homeostasis in later
life. We found positive correlations between blood glu-
cose levels and body weight, and between glucose levels
and visceral fat deposition. Previous studies have indi-
cated that glucose homeostasis in adulthood is pro-
grammed during gestation [78-80] at a time when the
hypothalamus is vulnerable to excitotoxic injury [1-6]; and
several prospective studies have found associations be-
tween early life adiposity and weight gain with the devel-
opment of diabetes in later life [81]. Our study
concluded when the animals reached 5 months of age
(mature adulthood). It would be of interest to ascer-
tain whether the ASP-induced impairment of glucose
homeostasis would still be apparent at a later time-point,
since it is known that glucose homeostasis deteriorates with
aging in C57Bl/6 J mice.Conclusions
Our experimental model provides a valid means of inves-
tigating the interaction between two ingested food addi-
tives, and demonstrates how ASP and MSG may interact
in vivo to promote weight gain and impair glucose
homeostasis. Studies of this nature are of relevance to
the human population, where consumption of food addi-
tives are almost impossible to avoid in today’s diet. How-
ever care must be taken in extrapolating our findings
further, and it will be important to investigate the inter-
actions between MSG and ASP in other species.Additional files
Additional file 1: Figure S1. Main effect interaction of the diet
group MSG, ASP and MSG+ASP (mean± SEM, n = 36 per diet
group).
Additional file 2: Table S1. Correlation analysis of insulin resistance
parameters, ASP and MSG intake and body characteristics in Control
(A), MSG (B), ASP (C) and the MSG+ASP diet (D) mice. Significant
correlations are indicated in bold by ** at the 0.01 level and * at the 0.05
level (2-tailed). Correlations in males (n = 18 per diet group) are indicated
in italics (top right), and correlations in female subjects are shown in the
bottom left of the table.
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